TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3934930

Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 60

Group type: COMPARATOR
Intervention: metrizamide
Number of subjects: 60
Study: 30549486

Group type: EXPERIMENTAL
Intervention: Citalopram (antidepressant)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study: 26808489

Group type: EXPERIMENTAL
Intervention: Peer support intervention
Number of subjects: 208

Group type: COMPARATOR
Intervention: Traditional training
Number of subjects: 208
Study: 24781568

Group type: EXPERIMENTAL
Intervention: BIS target of 35 (low group)
Number of subjects: 125

Group type: COMPARATOR
Intervention: SE target of 50 (high group)
Number of subjects: 125
Study: 22329472

Group type: EXPERIMENTAL
Intervention: Acamprosate (1998 mg/day)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 20213210

Group type: EXPERIMENTAL
Intervention: Survey responses from surgeons regarding adherence to evidence-based surgical practices.
Number of subjects: 110

Group type: COMPARATOR
Intervention: Survey responses from surgeons at different institutions and experience levels.
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Responses to 13 questions involving different aspects of gastrointestinal surgery.
Number of subjects: 110
Study: 17989696

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) therapy, started at a dose of 5 parts per million (p.p.m.), maximal dose 20 p.p.m.
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (inhaled oxygen placebo only)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) therapy
Number of subjects: 65
Study: 16046440

Group type: EXPERIMENTAL
Intervention: Flocculant-disinfectant
Number of subjects: 6650

Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite
Number of subjects: 6650

Group type: COMPARATOR
Intervention: Control
Number of subjects: 6650

Group type: COMPARATOR
Intervention: Control and Sodium hypochlorite
Number of subjects: 6650

Group type: EXPERIMENTAL
Intervention: Flocculant-disinfectant and Sodium hypochlorite
Number of subjects: 6650
Study: 12351491

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg t.i.d. for 3 days
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Cisapride and Placebo
Number of subjects: 7
Study: 10705707

Group type: EXPERIMENTAL
Intervention: propionyl‐L‐carnitine
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 9166505

Group type: EXPERIMENTAL
Intervention: 1.0 mg oral granisetron HCI twice a day for 7 days
Number of subjects: 230

Group type: COMPARATOR
Intervention: 10 mg oral prochlorperazine sustained-release capsules twice a day for 7 days
Number of subjects: 230
Study: 1901104

Group type: EXPERIMENTAL
Intervention: Intravenous medium-chain triglycerides (MCT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intravenous long-chain triglycerides (LCT)
Number of subjects: 18
Study: 7048918

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 93

Group type: COMPARATOR
Intervention: Adenine arabinoside (ara-A)
Number of subjects: 93
Study: 30922814

Group type: EXPERIMENTAL
Intervention: CNSA-001 (sepiapterin) 2.5–80 mg/kg
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: CNSA-001 (sepiapterin)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: CNSA-001 (sepiapterin) 5, 20 or 60 mg/kg (repeat daily dosing)
Number of subjects: 83
Study: 27928880

Group type: EXPERIMENTAL
Intervention: InterTAK Diagnostic Score
Number of subjects: 218
Study: 25872619

Group type: COMPARATOR
Intervention: Attention placebo control (APC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parent training program
Number of subjects: 0
Study: 24423077

Group type: EXPERIMENTAL
Intervention: Measured GFR using Iohexol
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: Estimated GFR (eGFR) based on serum creatinine and/or cystatin C
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: Urinary albumin-to-creatinine ratio
Number of subjects: 1300
Study: 23444761

Group type: EXPERIMENTAL
Intervention: Oral misoprostol (400 microg every four hours, up to three doses)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (400 microg every four hours, up to three doses)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vaginal misoprostol (600 microg primary dosage)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vaginal misoprostol (600 microg primary dosage) and continuation of oral dose
Number of subjects: 40
Study: 19006526

Group type: EXPERIMENTAL
Intervention: Organized weekly exercise for 13 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 31
Study: 17979896

Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 1296

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 1296
Study: 15343235

Group type: EXPERIMENTAL
Intervention: GHQ‐12 screening tool
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Optimal cutoff score of GHQ‐12
Number of subjects: 222
Study: 11591185

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (20 mg, inhaled twice a day; 5.2 mg, intranasally twice a day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate
Number of subjects: 32
Study: 9491869

Group type: EXPERIMENTAL
Intervention: Standardized instruction in pelvic muscle exercise
Number of subjects: 46

Group type: COMPARATOR
Intervention: Routine care with no systematic pelvic muscle exercise instruction (Control)
Number of subjects: 46
Study: 8149771

Group type: EXPERIMENTAL
Intervention: High-intensity training program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-intensity training program
Number of subjects: 0
Study: 3346988

Group type: EXPERIMENTAL
Intervention: Stepped care (SC) group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Referred care (RC) control group
Number of subjects: 0
Study: 31867713

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention
Number of subjects: 1591

Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 1591
Study: 29576514

Group type: EXPERIMENTAL
Intervention: Volunteer staff assistance
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Bin tops
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Sample 3D items with bin tops
Number of subjects: 10000
Study: 26093975

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 429
Study: 26431299

Group type: EXPERIMENTAL
Intervention: Subthreshold diode‐laser micropulse (SDM)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Half-dose verteporfin photodynamic therapy (hdPDT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (CSC observation)
Number of subjects: 62
Study: 24016498

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 2331

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2331
Study: 20956265

Group type: EXPERIMENTAL
Intervention: Double-bundle reconstruction
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Single-bundle reconstruction
Number of subjects: 32

Group type: COMPARATOR
Intervention: Anterior cruciate ligament-deficient knees
Number of subjects: 32
Study: 18458586

Group type: EXPERIMENTAL
Intervention: TLIF-A (anterior placement of the semilunar cage)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: TLIF-P (posterior placement of the semilunar cage)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Comparison between TLIF-A and TLIF-P
Number of subjects: 6
Study: 16959668

Group type: EXPERIMENTAL
Intervention: Tai chi program (practiced by 83 subjects)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Control group (728 subjects)
Number of subjects: 1200
Study: 14501621

Group type: EXPERIMENTAL
Intervention: Mosapride 60 mg twice daily
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Mosapride 30 mg three times daily
Number of subjects: 41

Group type: COMPARATOR
Intervention: Cisapride 20 mg twice daily
Number of subjects: 41
Study: 11486420

Group type: EXPERIMENTAL
Intervention: Patients with beta-thalassemia major
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 113
Study: 9759061

Group type: EXPERIMENTAL
Intervention: Chlorhexamed 0.1%
Number of subjects: 130

Group type: COMPARATOR
Intervention: Corsodyl 0.2%
Number of subjects: 130
Study: 7917745

Group type: EXPERIMENTAL
Intervention: Nabilone 2 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Metoclopramide 10 mg
Number of subjects: 60
Study: 3421202

Group type: EXPERIMENTAL
Intervention: 30 mg purified beta‐carotene supplement
Number of subjects: 30

Group type: COMPARATOR
Intervention: 12 mg beta‐carotene supplement
Number of subjects: 30

Group type: COMPARATOR
Intervention: 272 g cooked carrots
Number of subjects: 30

Group type: COMPARATOR
Intervention: 300 g cooked broccoli
Number of subjects: 30

Group type: COMPARATOR
Intervention: 180 g tomato juice
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 31549494

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 831

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 831
Study: 28296682

Group type: EXPERIMENTAL
Intervention: Anticipated death (withdrawal or withholding of treatment or brain death)
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Unexpected death (despite full-level care or sudden refractory cardiac arrest)
Number of subjects: 698
Study: 25539696

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 26

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 26
Study: 22686292

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg once daily for 6 months
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study: 21654733

Group type: EXPERIMENTAL
Intervention: TT genotype of the FKBP5 gene SNP rs1360780
Number of subjects: 2157

Group type: COMPARATOR
Intervention: CC/CT genotypes of the FKBP5 gene SNP rs1360780
Number of subjects: 2157

Group type: EXPERIMENTAL
Intervention: Physical abuse with TT genotype of rs1360780
Number of subjects: 2157
Study: 18985059

Group type: EXPERIMENTAL
Intervention: Psyllium (3.0 to 20.4 g per day)
Number of subjects: 1717

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1717
Study: 17119523

Group type: EXPERIMENTAL
Intervention: Active sports drink (whey and orange juice)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (diluted apple juice)
Number of subjects: 18
Study: 15152887

Group type: EXPERIMENTAL
Intervention: Minimal-contact lifestyle interventions
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study: 12761949

Group type: EXPERIMENTAL
Intervention: Regional intra-arterial chemotherapy (IACT)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Systemic chemotherapy (SCT)
Number of subjects: 121
Study: 9056054

Group type: EXPERIMENTAL
Intervention: Lanreotide (100 micrograms h-1 after a bolus of 100 micrograms 15 min before the study)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lanreotide
Number of subjects: 8
Study: 8346563

Group type: EXPERIMENTAL
Intervention: Lorazepam 2.5 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 30170329

Group type: EXPERIMENTAL
Intervention: Pregabalin (75-600 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 60
Study: 26931509

Group type: EXPERIMENTAL
Intervention: Energy drink (2 mg caffeine per kg body weight; low dose)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Energy drink (3 mg caffeine per kg body weight; medium dose)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Coffee (2 mg caffeine per kg body weight)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 250 ml water
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 1 16 oz can of energy drink (16 oz Monster)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 1 24 oz can of energy drink (24 oz Monster)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 1 packet of Keurig K-Cup Starbucks coffee
Number of subjects: 15
Study: 25203488

Group type: EXPERIMENTAL
Intervention: High-dose alcohol
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Low-dose alcohol
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 22569489

Group type: COMPARATOR
Intervention: Aerobic Exercise (AE)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Combined Aerobic Resistance Exercise (ARE)
Number of subjects: 65
Study: 21719808

Group type: EXPERIMENTAL
Intervention: Repair with amalgam (n = 20)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sealing of defective margins (n = 23)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Refinishing (n = 23)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Replacement (n = 22)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No treatment (n = 25)
Number of subjects: 50
Study: 18653326

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate (two doses)
Number of subjects: 546
Study: 16889588

Group type: EXPERIMENTAL
Intervention: Suicidal ideation in individuals with psychosis
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Affective dysfunction (including distress in response to hallucinations and delusions)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Positive symptom distress
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Frequency of auditory hallucinations and preoccupation with delusions
Number of subjects: 290
Study: 12924702

Group type: EXPERIMENTAL
Intervention: Aprotinin (240 mg/m2 administered intravenously over 20 minutes, followed by infusions of 56 mg/m2/hr)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 10808043

Group type: EXPERIMENTAL
Intervention: Clonazepam (2 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (atmospheric compressed air)
Number of subjects: 22
Study: 8858630

Group type: EXPERIMENTAL
Intervention: Apraclonidine 0.5%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Apraclonidine 1%
Number of subjects: 0
Study: 1353708

Group type: EXPERIMENTAL
Intervention: Esmolol (500 micrograms.kg‐1 i.v. bolus followed by 150‐300 micrograms.kg‐1.min‐1 maintenance infusion)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Labetalol (5 mg i.v. bolus followed by 5 mg increments as needed up to a maximum of 1 mg.kg‐1)
Number of subjects: 22
Study: 6337524

Group type: EXPERIMENTAL
Intervention: Extradural diamorphine 0.1 mg/kg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Intramuscular diamorphine 0.1 mg/kg
Number of subjects: 39
Study: 31485931

Group type: EXPERIMENTAL
Intervention: neoClose® system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard suture closure
Number of subjects: 0
Study: 29475804

Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (10 mg or 25 mg) plus emtricitabine (200 mg)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Abacavir (600 mg) plus lamivudine (300 mg)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide plus emtricitabine
Number of subjects: 501

Group type: COMPARATOR
Intervention: Abacavir plus lamivudine
Number of subjects: 501
Study: 26916196

Group type: EXPERIMENTAL
Intervention: Care bundles for patients with COPD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 24564252

Group type: EXPERIMENTAL
Intervention: Immunohistochemistry (IHC) assessment of PTEN loss
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: IHC assessment concordance with Taqman® copy number variation (CNV)
Number of subjects: 51
Study: 23253713

Group type: EXPERIMENTAL
Intervention: Small laser spot PDT
Number of subjects: 52
Study: 20664019

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 5145

Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 5145
Study: 17805089

Group type: EXPERIMENTAL
Intervention: Quercetin (1000 mg.d(‐1))
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 14985995

Group type: EXPERIMENTAL
Intervention: Healthy subjects (n=10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patients with chronic obstructive pulmonary disease (n=10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Heart failure patients (n=10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Healthy volunteers (n=7) at rest
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Healthy volunteers (n=7) during exercise
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Healthy volunteers (n=7)
Number of subjects: 30
Study: 11133794

Group type: EXPERIMENTAL
Intervention: IVIg (500 mg/kg/day for 5 consecutive days, once a month for 3 months)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Combined analysis of IVIg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Self-evaluation score
Number of subjects: 19

Group type: COMPARATOR
Intervention: Electrophysiological studies
Number of subjects: 19

Group type: COMPARATOR
Intervention: IgM anti-GM1 titres
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: High anti-GM1 titres (>3200)
Number of subjects: 19
Study: 9700879

Group type: EXPERIMENTAL
Intervention: HIV infection patients with CD4+ T-lymphocytes below 200/1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIV infection patients with non-specific pulmonary diseases
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All stages of HIV infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early stages of HIV infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Later stages of HIV infection
Number of subjects: 0
Study: 7518629

Group type: EXPERIMENTAL
Intervention: 0.0005% iloprost solution
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: 0.002% iloprost solution
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 148
Study: 2594915

Group type: EXPERIMENTAL
Intervention: Received nicotine gum
Number of subjects: 77

Group type: COMPARATOR
Intervention: Received placebo gum
Number of subjects: 77

Group type: COMPARATOR
Intervention: Not told which gum received
Number of subjects: 77

Group type: COMPARATOR
Intervention: Instructions (told received nicotine vs told received placebo)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Instructions and nicotine interaction
Number of subjects: 77
Study: 30980539

Group type: EXPERIMENTAL
Intervention: Metformin at baseline
Number of subjects: 1731

Group type: EXPERIMENTAL
Intervention: Metformin during concomitant radiochemotherapy (TMZ/RT)
Number of subjects: 1731

Group type: EXPERIMENTAL
Intervention: Metformin monotherapy at baseline
Number of subjects: 1731

Group type: EXPERIMENTAL
Intervention: Metformin monotherapy during TMZ/RT
Number of subjects: 1731

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus or increased nonfasting glucose levels
Number of subjects: 1731
Study: 27727202

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon angioplasty (DCB)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Plain old balloon angioplasty (POBA)
Number of subjects: 106
Study: 25736783

Group type: EXPERIMENTAL
Intervention: EIMD (n = 9)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: EIMD trial 2
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: EIMD trial 1
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (CON, n = 7)
Number of subjects: 16
Study: 23574808

Group type: EXPERIMENTAL
Intervention: Intranasal CO2
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (air)
Number of subjects: 48
Study: 21646929

Group type: EXPERIMENTAL
Intervention: Intratympanic steroid injections (ITSIs)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intratympanic normal saline injection (ITNI)
Number of subjects: 60
Study: 18825421

Group type: EXPERIMENTAL
Intervention: Palonosetron 0.25 mg
Number of subjects: 240

Group type: COMPARATOR
Intervention: Granisetron 3 mg
Number of subjects: 240
Study: 17088580

Group type: EXPERIMENTAL
Intervention: Inhaled insulin
Number of subjects: 4023

Group type: COMPARATOR
Intervention: Subcutaneous insulin
Number of subjects: 4023
Study: 14583899

Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 9
Study: 11199238

Group type: EXPERIMENTAL
Intervention: Palliative cancer care workshop
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group of non-participants
Number of subjects: 68
Study: 9064945

Group type: EXPERIMENTAL
Intervention: Quinaprilat (low dose: 0.5 and 1.0 mg, medium dose: 1.0 and 2.5 mg, high dose: 5.0 and 10.0 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 1591513

Group type: EXPERIMENTAL
Intervention: 40 mg i.v. cocaine injections
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3936095

Group type: EXPERIMENTAL
Intervention: Nicotinic acid (141.7 mg)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Xanthinol nicotinate (500 mg, containing 141.7 mg nicotinic acid)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 96
Study: 26699666

Group type: EXPERIMENTAL
Intervention: 5 mg donepezil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30786253

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (60 mg)
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1002
Study: 28698321

Group type: EXPERIMENTAL
Intervention: oral oseltamivir plus inhaled zanamivir (arm OZ)
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: oseltamivir plus inhaled placebo (arm Opz)
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: oral placebo plus inhaled zanamivir (arm poZ)
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: inhaled therapy
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: oral therapy
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: antibiotic coprescriptions
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: active combination treatment
Number of subjects: 541
Study: 26027851

Group type: EXPERIMENTAL
Intervention: IMRT
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Overall patient cohort
Number of subjects: 22